J M Calvo-Villas1, A Martín2, E Conde3, A Pascual4, I Heras5, R Varela6, J de la Rubia7, M J Ramirez8, J L Díez-Martín9, C Panizo10, M J Rodríguez-Salazar11, M J Pascual12, E M Donato13, E González-Barca14, M D Caballero15. 1. Department of Hematology, Hospital Doctor José Molina Orosa, Arrecife de Lanzarote. Electronic address: jmcvillas@hotmail.com. 2. Department of Hematology, Complejo Asistencial de Zamora, Zamora. 3. Department of Hematology, Hospital Marqués de Valdecilla, Santander. 4. Department of Hematology, Hospital Clinico Universitario San Carlos, Madrid. 5. Department of Hematology, Hospital Morales Meseguer, Murcia. 6. Department of Hematology, Hospital Juan Canalejo, La Coruña. 7. Department of Hematology, Hospital La Fe, Valencia. 8. Department of Hematology, Hospital General de Jerez, Jerez de la Frontera. 9. Department of Hematology, Hospital Gregorio Marañón, Madrid. 10. Department of Hematology, Clínica Universitaria de Navarra, Pamplona. 11. Department of Hematology, Hospital Universitario de Canarias, Tenerife. 12. Department of Hematology, Hospital Carlos Haya, Malaga. 13. Department of Hematology, Hospital General de Castellón, Castellón. 14. Department of Hematology, Institut Catalá d'Oncología-Hospital Duran i Reynals, L'Hospitalet de Llobregat. 15. Department of Hematology, Hospital Clínico Universitario, Salamanca, Spain.
Abstract
BACKGROUND: We have investigated if rituximab-based salvage regimens improve response rates and survival of patients with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: We have retrospectively analyzed 82 patients with DLBCL who received salvage therapy for relapse or progression after ASCT. Patients were divided into two groups, according to whether rituximab-based salvage regimens were given (n = 42, 'R-' group) or not (n = 40, 'R+' group) after ASCT. RESULTS: Patients in the R+ group had better complete remission (CR) (55% versus 21.4%, P = 0.006) and overall response (OR) (75% versus 40.4%, P = 0.001) rates, and better 3-year event-free survival (EFS) (37% versus 9%, P = 0.002) and overall survival (OS) (50% versus 20%, P = 0.005) than patients in the R- group. Patients retreated with rituximab had better CR (42.9% versus 21.4%, P = 0.032) and OR (66.7% versus 40.4%, P = 0.019) rates, and better OS (36.2% versus 20% at 3 years, P = 0.05) and EFS (36.2% versus 9% at 3 years, P = 0.05) than patients who received chemotherapy alone at relapse after ASCT. CONCLUSIONS: The addition of rituximab to salvage chemotherapy improves response rates and EFS in patients with relapsed DLBCL after ASCT. These patients may benefit from rituximab retreatment, although larger prospective studies are needed to confirm these results.
BACKGROUND: We have investigated if rituximab-based salvage regimens improve response rates and survival of patients with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: We have retrospectively analyzed 82 patients with DLBCL who received salvage therapy for relapse or progression after ASCT. Patients were divided into two groups, according to whether rituximab-based salvage regimens were given (n = 42, 'R-' group) or not (n = 40, 'R+' group) after ASCT. RESULTS:Patients in the R+ group had better complete remission (CR) (55% versus 21.4%, P = 0.006) and overall response (OR) (75% versus 40.4%, P = 0.001) rates, and better 3-year event-free survival (EFS) (37% versus 9%, P = 0.002) and overall survival (OS) (50% versus 20%, P = 0.005) than patients in the R- group. Patients retreated with rituximab had better CR (42.9% versus 21.4%, P = 0.032) and OR (66.7% versus 40.4%, P = 0.019) rates, and better OS (36.2% versus 20% at 3 years, P = 0.05) and EFS (36.2% versus 9% at 3 years, P = 0.05) than patients who received chemotherapy alone at relapse after ASCT. CONCLUSIONS: The addition of rituximab to salvage chemotherapy improves response rates and EFS in patients with relapsed DLBCL after ASCT. These patients may benefit from rituximab retreatment, although larger prospective studies are needed to confirm these results.
Authors: Ping-Chiao Tsai; Francisco J Hernandez-Ilizaliturri; Naveen Bangia; Scott H Olejniczak; Myron S Czuczman Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: A R Rezvani; A S Kanate; B Efron; S Chhabra; H E Kohrt; J A Shizuru; G G Laport; D B Miklos; J E Benjamin; L J Johnston; S Arai; W-K Weng; R S Negrin; S Strober; R Lowsky Journal: Bone Marrow Transplant Date: 2015-07-06 Impact factor: 5.483